Related Experiment Video
Updated: Dec 11, 2025

12:18
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.8K
Patient Perspectives about Mild Cognitive Impairment: A Systematic Review
1Clinical Psychology Research, Currently Undertaking Clinical Psychology Doctoral Training, School of Psychology, University of Birmingham, Birmingham, UK.
Clinical Gerontologist
|August 22, 2020
Summary
Patients
Area of Science:
- Gerontology
- Neurology
- Psychology
Background:
- Mild cognitive impairment (MCI) is a controversial diagnosis with unclear patient understanding and perceived benefit of disclosure.
- Prognostic uncertainty and the nebulous nature of MCI contribute to patient and caregiver confusion.
Purpose of the Study:
- To explore patient and care partner perceptions and experiences of the Mild Cognitive Impairment (MCI) label.
- To understand the impact of being informed about an MCI diagnosis on individuals and their support systems.
Main Methods:
- A systematic review of literature from ISI Web of Science, PubMed, and PsycINFO was conducted.
- Thematic synthesis was used to analyze findings from fourteen selected papers adhering to PRISMA guidelines.
Main Results:
- Patient adjustment to the MCI label is influenced by individual differences, coping styles, and personal experiences.
- Perceptions of MCI's utility are affected by the construct's ambiguity and available information.
- Care partners express uncertainty regarding MCI's meaning and how to manage cognitive difficulties.
Conclusions:
- Patient and care partner perspectives on MCI are shaped by the quality of information and support provided by clinicians.
- Tailored support and clear communication from healthcare professionals are crucial for improving patient adjustment and coping with MCI.
Related Concept Videos
Alzheimer's Disease: Overview
1.4K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.4K
Cognitive Development During Adulthood
621
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
621
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
425
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
425
Dementia
413
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
413
Alzheimer's Disease: Treatment
647
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
647
Pharmacodynamics in Geriatric Patients: Effects of Age
122
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
122

